Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Short-course drug therapy for tuberculosis.

M A Stratton, M T Reed

    Clinical Pharmacy
    |December 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Short-course chemotherapy (SCC) for tuberculosis is effective but has not yet shown clear advantages over longer treatments in cost, compliance, or toxicity. Further research is needed to optimize SCC regimens, especially in the United States.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The effects of 12, 30, or 48 hours of road transport on the physiological and behavioral responses of sheep.

    Journal of animal science·2010
    Same author

    Historicizing inversion: or, how to make a homosexual.

    History of the human sciences·2008
    Same author

    The global network on dental education: a new vision for IFDEA.

    European journal of dental education : official journal of the Association for Dental Education in Europe·2008
    Same author

    Pharmacodynamic considerations in the elderly.

    Experimental lung research·2006
    Same author

    Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients.

    Archives of internal medicine·2000
    Same author

    Sympathomimetics for acute severe asthma: should only beta 2-selective agonists be used?

    DICP : the annals of pharmacotherapy·1990
    Same journal

    Criteria for use of epoetin alfa in adult cancer and orthopedic-surgery patients.

    Clinical pharmacy·1993
    Same journal

    Accuracy of unbound-quinidine concentration determination after ultrafiltration.

    Clinical pharmacy·1993
    Same journal

    Modified Michaelis-Menten equation for estimating unbound-phenytoin concentrations.

    Clinical pharmacy·1993
    Same journal

    Predicting vancomycin pharmacokinetics by using aminoglycoside pharmacokinetics.

    Clinical pharmacy·1993
    Same journal

    Efficacy of nutritional supplements used by athletes.

    Clinical pharmacy·1993
    Same journal

    Low-molecular-weight heparins for the treatment of deep-vein thrombosis.

    Clinical pharmacy·1993
    See all related articles

    Area of Science:

    • Pulmonary Medicine
    • Infectious Diseases
    • Pharmacology

    Background:

    • Pulmonary tuberculosis treatment traditionally involves 18- to 24-month regimens.
    • Short-course chemotherapy (SCC), defined as treatment for nine months or less, is being increasingly explored.
    • Establishing definitive advantages of SCC over conventional therapy is crucial.

    Purpose of the Study:

    • To compare the cost, patient compliance, and toxicity of SCC versus conventional tuberculosis treatment.
    • To evaluate the efficacy of various SCC regimens.
    • To examine the future use of SCC in the United States.

    Main Methods:

    • Review and evaluation of published studies on SCC efficacy, including those from the East African-British Medical Research Council, Hong Kong Chest Service, and British Medical Research Council.

    Related Experiment Videos

  • Analysis of treatment guidelines and clinical practices in the United States.

    • Main Results:

    • No definitive advantage for SCC in terms of cost, compliance, or adverse effects has been established compared to conventional therapy.
    • Studies confirm the efficacy of six-month multiple-drug regimens containing rifampin and the sterilizing activity of pyrazinamide.
    • Intermittent drug regimens have shown acceptable relapse rates, particularly those including pyrazinamide.

    Conclusions:

    • SCC regimens, especially those incorporating pyrazinamide, demonstrate efficacy in treating pulmonary tuberculosis.
    • While SCC use is increasing in the US for uncomplicated cases, its wider adoption requires more clinical experience and potentially updated guidelines.
    • Further research is needed to fully establish SCC's benefits and optimize its application in the US context.